Trial
NCT02808429
Efficacy and Safety of Atacicept in IgA Nephropathy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
IgA Nephropathy
Intervention
Placebo
Why stopped
Study was terminated early as per sponsor decision due to unexpectedly slow enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-25